TME Pharma (DB:0N6A) - Hisse Senedi Fiyatı, Haberler ve Analizler

0N6A Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan TME Pharma N.V., Almanya'da kanser tedavisi için tescilli terapötiklerin geliştirilmesine odaklanmaktadır.

Şirket hakkında

0N6A temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 12% oranında azaldı

Geliri 1 milyon ABD dolarından az ( €0 )

Anlamlı bir piyasa değeri yok ( €5M )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

+ 2 daha fazla risk

TME Pharma N.V. Rakipler

4SC

DB:VSC

€63.3m

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€27.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti TME Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€0.12
52 Haftanın En Yüksek Seviyesi	€0.58
52 Haftanın En Düşük Seviyesi	€0.09
Beta	1.77
11 Aylık Değişim	-4.45%
3 Aylık Değişim	-8.26%
1 Yıllık Değişim	-76.92%
33 Yıllık Değişim	-99.53%
5 Yıllık Değişim	-99.68%
Halka arzdan bu yana değişim	-99.95%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0N6A	DE Biotechs	DE Pazar
7D	-3.9%	-1.3%	0.02%
1Y	-76.9%	-11.5%	19.6%

Getiri vs. Endüstri: 0N6A geçen yıl % -15.1 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0N6A geçen yıl % 13.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0N6A's price volatile compared to industry and market?
0N6A volatility
0N6A Average Weekly Movement	10.7%
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 0N6A hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0N6A 'nin haftalık oynaklığı son bir yılda 21% dan 11% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	13	Aram Mangasarian	www.tmepharma.com

Klinik aşamada bir biyofarmasötik şirketi olan TME Pharma N.V., Almanya'da kanser tedavisi için tescilli terapötiklerin geliştirilmesine odaklanmaktadır. Spiegelmer platformu, metastatik pankreas ve kolorektal kanser, glioblastoma ve miyelom gibi çeşitli kanser endikasyonları için bir kombinasyon tedavisi olarak geliştirilmekte olan lider kanser ilaç adayı NOX-A12 de dahil olmak üzere klinik aşamadaki ürün adaylarından oluşan tescilli bir boru hattına sahiptir. Şirket ayrıca diyabetik nefropati tedavisi için Faz 1/2 klinik çalışmasını tamamlamış olan NOX-E36'yı geliştirmektedir.

TME Pharma N.V. Temel Bilgiler Özeti

TME Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0N6A temel i̇stati̇sti̇kler
Piyasa değeri	€5.84m
Kazançlar(TTM)	-€6.32m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.9x

F/K Oranı

0N6A aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0N6A gelir tablosu (TTM)
Gelir	€0
Gelir Maliyeti	€0
Brüt Kâr	€0
Diğer Giderler	€6.33m
Kazançlar	-€6.32m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.15
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

0N6A uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0N6A Stoklara Genel Bakış

Ödüller

Risk Analizi

TME Pharma N.V. Rakipler

DB:VSC

€63.3m

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€27.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

TME Pharma N.V. Provides Clinical Update

TME Pharma N.V. Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board

New major risk - Negative shareholders equity

TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer

TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer

Recent updates

TME Pharma N.V. Provides Clinical Update

TME Pharma N.V. Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board

New major risk - Negative shareholders equity

TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer

TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer

TME Pharma N.V. Announces FDA Clearance of Investigational New Drug (Ind) Application for Nox-A12 Phase 2 Trial in Brain Cancer

TME Pharma N.V. announced that it expects to receive €1.479999 million in funding

TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer

TME Pharma N.V. announced that it has received €2.7 million in funding

New major risk - Financial position

TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer

TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting

Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer

TME Pharma N.V. Provides Positive Data Update on Best Response to Therapy with First Complete Response in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near- Complete Response

TME Pharma N.V. Announces Positive 15-Month Survival Data from Gloria Expansion Arm Evaluating NOX-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma

TME Pharma N.V. Receives Investigational New Drug (IND) Approval for NOX-A12 From the US FDA

TME Pharma N.V., Annual General Meeting, Jun 29, 2023

TME Pharma N.V. Provides Positive Clinical Update and 14-Month Survival Data from Gloria Expansion Arm Evaluating Nox-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma

Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma

TME Pharma N.V. Announces Executive Changes

TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in Brain Cancer Presented at the Society for Neuro-oncology 2022 Annual Meeting

TME Pharma Announces Publication of Abstract Disclosing Positive Interim Results from Bevacizumab Expansion Arm of NOX-A12 Gloria Phase 1/2 Brain Cancer Clinical Trial

TME Pharma N.V. Announces Data Safety Monitoring Board Validated Safety Data from the Initial Four Weeks of Treatment of the First Patient Enrolled in the GLORIA Phase 1/2 Clinical Trial Expansion Arm with NOX A12

TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial

NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, Effective September 30, 2022

NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observed With NOX-A12 in Combination With Radiotherapy and Bevacizumab in Brain Cancer

NOXXON Pharma N.V., Annual General Meeting, Jun 29, 2022

NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASCO Annual Meeting and Invitation to a Dedicated KOL Event

Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments

Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to Be Presented during 2022 ASCO Annual Meeting

NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial With NOX-A12 in Brain Cancer Patients

NOXXON Pharma N.V. announced that it expects to receive €17 million in funding from Atlas Special Opportunities LLC

NOXXON Pharma N.V. Announces Enrolment of First Patient in the Expansion of the NOX-A12 Phase 1/2 Trial in Brain Cancer

NOXXON Pharma N.V. Presents New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in Brain Cancer at the Society for Neuro-Oncology Annual Meeting 2021

NOXXON Pharma N.V Enrolls Last Brain Cancer Patient in Dose Escalation Portion of GLORIA Study and Confirms Phase 1/2 Read-Out

NOXXON Provides Update on NOX-A12 Clinical Programs

Member of Supervisory Board J. deBethizy has left the company

Independent Member of the Supervisory Board Bertram Köhler has left the company

NOXXON Pharma N.V. Announces Positive Results from the Second Cohort in its Phase 1/2 Study of Nox-A12

NOXXON Announces Positive Results From Second Cohort in Phase 1/2 NOX-A12 Brain Cancer Trial

Noxxon Pharma N.V. Announces Data Safety Monitoring Board Validates NOX-A12 Highest Dose in Phase 1/2 Brain Cancer Trial

Noxxon Pharma N.V. Announces That the Data Safety Monitoring Board Analyzed Safety Data from the Initial Four Weeks of Treatment of the First Patient Enrolled in the Third and Final Dose Cohort of the NOX-A12 Plus

NOXXON Enrolls First Patient in the High Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain Cancer

NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board

NOXXON Pharma N.V. Appoints Jose Saro as Chair of Scientific Advisory Board

New 90-day high: €0.65

NOXXON Pharma N.V. Announces Initiation of NOX-A12 Manufacturing for Future Clinical Studies

NOXXON Pharma N.V. Announces That Data Safety Monitoring Board Validates Further Nox-A12 Dose Escalation in Phase 1/2 Brain Cancer Study

NOXXON Pharma N.V. Announces Completion of 6-Month Therapy for Low-Dose Cohort in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy

Noxxon Pharma N.V. Announces Three Additional Clinical Centers to Recruit Patients for Nox-A12 Brain Cancer Trial

New 90-day low: €0.41

Noxxon Announces Successful Completion of Patient Recruitment for Second Dose Cohort in Phase 1/2 Brain Cancer Study of Nox-A12 Plus Radiotherapy

NOXXON Pharma N.V. Presents Final Clinical Data from Phase 1/2 NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020

NOXXON Pharma N.V. announced that it has received €0.499999 million in funding

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

TME Pharma N.V. Temel Bilgiler Özeti